BioSpace7h
Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial Failure
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
BioPharma Dive6h
Gilead withdraws Trodelvy in bladder cancer
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.
Fintel on MSN10h
Bernstein Initiates Coverage of Gilead Sciences (GILD) with Outperform Recommendation
Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...
Gilead voluntarily withdraws urothelial cancer drug in US
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
ENDPOINTS NEWS7h
Gilead pulls Trodelvy's ac­cel­er­at­ed la­bel in blad­der can­cer af­ter drug failed con­fir­ma­to­ry study
Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...
National Review22h
National Review – Top Stories
The objective was to peel some soft Trump supporters away from his coalition, but she gave them no reason to reconsider. Last night, Harris was forced to face tough questions about the Biden ...
pharmaphorum22h
J&J’s Spravato for depression ‘should be much cheaper’
The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and 52% cheaper to meet its value ...